TABLE 3.
C. neoformans CFUs after coculture of PMNs with 1,000 yeast cells treated with IgM antibodies plus rabbit or human complement sources
| Antibody and/or seruma | CFUb |
|---|---|
| None (PBS) | 727 ± 135 |
| Heated rabbit serum | 633 ± 77 |
| Unheated rabbit serum | 587 ± 47c |
| 2E9 | 541 ± 86c |
| 2E9 + heated rabbit serum | 502 ± 66d |
| 2E9 + unheated rabbit serum | 304 ± 90d |
| None (PBS) | 723 ± 42.9 |
| Factor-B-deficient serum | 723 ± 34.7 |
| Myeloma IgM + factor-B-deficient serum | 756 ± 42.7 |
| 2E9 + factor-B-deficient serum | 350 ± 65e |
a
Antibodies (2E9 and myeloma antibody) were used at concentrations of 25 μg/ml, and complement sources (unheated rabbit serum, heated rabbit serum, and human factor-B-deficient serum) were used at 10% concentrations. Results for rabbit serum represent three different experiments, and those for factor-B-deficient serum represent two experiments.
b
The E/T ratio was 10:1 (PMNs to yeast cells).
c
P < 0.01 versus PBS by the Mann-Whitney U test.
d
P < 0.005 versus PBS by the Mann-Whitney U test.
e
P < 0.005 for factor-B-deficient serum versus PBS by the Mann-Whitney U test.